A Phase 2 clinical trial of RT001 in patients with Amyotrophic Laterial Sclerosis (ALS)
Latest Information Update: 17 Feb 2021
At a glance
- Drugs RT 001 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- 17 Feb 2021 New trial record
- 11 Feb 2021 According to a Retrotope media release, first patient dosing expected in the first quarter of 2021 and data read out anticipated by the end of 2021. This trial is being informed by the company single-arm expanded access program study for RT001 in ALS.